Monosodium Glutamate: Review on Preclinical and Clinical Reports

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0002-7073-2907en_US
dc.authoridhttps://orcid.org/0000-0002-8076-9965en_US
dc.authoridhttps://orcid.org/0000-0003-4040-4547en_US
dc.authoridhttps://orcid.org/0000-0001-7982-6988en_US
dc.contributor.authorBayram, Hatice Merve
dc.contributor.authorAkgöz, Hasan Fatih
dc.contributor.authorKızıldemir, Özgür
dc.contributor.authorÖztürkcan, S. Arda
dc.date.accessioned2023-03-17T14:25:01Z
dc.date.available2023-03-17T14:25:01Z
dc.date.issued2023en_US
dc.departmentSağlık Bilimleri Fakültesien_US
dc.description.abstractMonosodium glutamate (MSG) is a flavor enhancer derived from L-glutamic acid, a naturally occurring amino acid in various food products. Although MSG is generally considered safe by food safety regulatory agencies, it is claimed that MSG administration may lead to neurotoxicity, cardiotoxicity, hepatic and renal disorders, and metabolic disorders. This review aimed to provide a comprehensive perspective on the potential risks of MSG administration, based on results obtained from preclinical and clinical studies regarding the alleged toxic effects of MSG. A literature search was conducted in Scopus, Google Scholar, Pubmed, and ScienceDirect databases for preclinical and clinical studies that evaluated the adverse effects of MSG administration on health. Preclinical studies showed that MSG administration was associated with obesity, cardiotoxicity, hepatotoxicity, kidney toxicity, neurotoxicity, anemia, spleen toxicity, lipid and glucose metabolism alteration, negative effects of fertility, coagulant system, and microbiota. However, clinical studies have focused mostly on MSG effects on appetite and energy expenditure. Additionally, MSG administration was associated with obesity, neurotoxicity, and increasing pain symptoms whereas did not affect the microbiota. Also, MSG can be used as a therapeutic agent in dementia patients by showing a positive effect on cognitive performance.en_US
dc.identifier.doi10.33263/BRIAC132.149en_US
dc.identifier.endpage25en_US
dc.identifier.issn2069-5837
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85127853555en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://hdl.handle.net/11363/4169
dc.identifier.urihttps://doi.org/
dc.identifier.volume13en_US
dc.identifier.wosWOS:000828471200044en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBIOINTERFACE RESEARCH APPLIED CHEMISTRYBIOINTERFACE RESEARCH APPLIED CHEMISTRY, BUCURESTI 00000, ROMANIAen_US
dc.relation.ispartofBiointerface Research in Applied Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectmonosodium glutamateen_US
dc.subjecttoxicityen_US
dc.subjectpreclinical studiesen_US
dc.subjectclinical studiesen_US
dc.titleMonosodium Glutamate: Review on Preclinical and Clinical Reportsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
BRIAC132.149.pdf
Boyut:
352.98 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale / Article
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.56 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Web of Science ve Scopus Atıf Dizinlerindeki Yayınlar
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu